SCHEMBL5537347

SCHEMBL5537347

CC(C)(C)OC(=O)N1CCN(C(=O)c2ccc(O)cc2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.70
MEN1 O00255 2/20 0.70
HDAC4 P56524 1/20 0.56
ABL1 P00519 1/20 0.55
RIN1 Q13671 1/20 0.55
EPHX2 P34913 1/20 0.54
PDK1 Q15118 1/20 0.52
PDK2 Q15119 1/20 0.52
PDK3 Q15120 1/20 0.52
PDK4 Q16654 1/20 0.52
ESR2 Q92731 1/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HTT P42858 1/20 0.50
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
CNR2 P34972 1/20 0.48
GPR119 Q8TDV5 2/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8252454 0.89 KMT2A (0.72) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL26823793 0.88 MEN1 (0.57) KMT2AMEN1HDAC4ESR2POLB
SCHEMBL3900270 0.88 KMT2A (0.70) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL29188760 0.88 KMT2A (0.70) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL13872055 0.86 KMT2A (0.68) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL2928630 0.86 KMT2A (0.68) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL3093877 0.86 MEN1 (0.68) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL110336 0.86 KMT2A (0.68) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL2365799 0.86 KMT2A (0.68) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL1256025 0.86 KMT2A (0.92) KMT2AMEN1HDAC4ABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885MEN1 3295/4885HDAC4 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.